A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

被引：0
作者：
Spurgeon, Stephen [1 ]
Chen, Andy I.
Okada, Craig [2 ]
Parekh, Samir [3 ]
Leshchenko, Violetta V. [3 ]
Palmbach, Gundula
Ratterree, Bashi
Subbiah, Nan
Capper, Christine [4 ]
Epner, Elliot M. [5 ]
机构：
[1] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Knight Canc Inst, Portland, OR 97201 USA
[2] OHSU Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR USA
[3] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10467 USA
[4] Penn State Hershey Canc Inst, Hershey, PA USA
[5] Penn State Univ, Hershey Canc Ctr, Hershey, PA USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：203 / 203
页数：1
相关论文
共 50 条
  • [31] The final results of a phase I study using velcade (bortezomib), cladribine, and rituximab (VCR) in treating elderly patient with mantle cell lymphoma
    Pu, Jeffrey J.
    Berger, Kristin
    Claxton, David
    Drabick, Joseph
    Loughran, Thomas
    Epner, Elliot
    CANCER RESEARCH, 2024, 84 (07)
  • [32] Initial Results of a Phase II Study of Sequential Chemotherapy and Lenalidomide Followed By Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
    Kumar, Anita
    Zelenetz, Andrew D.
    Batlevi, Connie Lee
    Caron, Philip
    Dogan, Ahmet
    Drullinsky, Pamela
    Gerecitano, John
    Hamilton, Audrey
    Hamlin, Paul A.
    Laraque, Leana
    Matasar, Matthew J.
    McCall, Susan Jennifer
    Moskowitz, Alison J.
    Moskowitz, Craig H.
    Owens, Colette
    Pichardo, Janine
    Schoder, Heiko
    Sigler, Allison
    Straus, David J.
    Younes, Anas
    BLOOD, 2018, 132
  • [33] Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma
    Cowan, Andrew J.
    Stevenson, Phillip A.
    Gooley, Ted A.
    Frayo, Shani L.
    Oliveira, George R.
    Smith, Stephen D.
    Green, Damian J.
    Roden, Jennifer E.
    Pagel, John M.
    Wood, Brent L.
    Press, Oliver W.
    Gopal, Ajay K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (04) : 583 - 590
  • [34] Phase II trial of bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or elderly mantle cell lymphoma in Japan.
    Ishizawa, Kenichi
    Ogura, Michinori
    Maruyama, Dai
    Abe, Yasunobu
    Ando, Kiyoshi
    Izutsu, Koji
    Terui, Yasuhito
    Yoshitaka, Imaizumi
    Fukuhara, Noriko
    Uchida, Toshiki
    Choi, Ilseung
    Ohmachi, Ken
    Yamamoto, Go
    Tobinai, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan
    Michinori Ogura
    Kenichi Ishizawa
    Dai Maruyama
    Naokuni Uike
    Kiyoshi Ando
    Koji Izutsu
    Yasuhito Terui
    Yoshitaka Imaizumi
    Kunihiro Tsukasaki
    Kenshi Suzuki
    Tohru Izumi
    Kensuke Usuki
    Tomohiro Kinoshita
    Masafumi Taniwaki
    Nobuhiko Uoshima
    Junji Suzumiya
    Mitsutoshi Kurosawa
    Hirokazu Nagai
    Toshiki Uchida
    Noriko Fukuhara
    Ilseung Choi
    Ken Ohmachi
    Go Yamamoto
    Kensei Tobinai
    International Journal of Hematology, 2017, 105 : 470 - 477
  • [36] Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study
    Shadman, Mazyar
    Gopal, Ajay K.
    Press, Oliver
    Maloney, David G.
    Mawad, Raya
    Wadsworth, Troy
    Dennie, Trevor W.
    Schultheiss, Karl
    Kojouri, Kiarash
    Kammerer, Britt E.
    Pagel, John M.
    BLOOD, 2016, 128 (22)
  • [37] Phase I trial of bortezomib in combination with rituximab-HyperCVAD/methotrexate and cytarabine for untreated mantle cell lymphoma
    Romaguera, J. E.
    Pro, B.
    Fayad, L.
    McLaughlin, P.
    Wang, M.
    Weaver, P.
    Hartig, K.
    Hagemeister, F.
    Rodriguez, M. A.
    Younes, A.
    Samaniego, F.
    Fanale, M.
    Kwak, L.
    Feldman, T.
    Goy, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 214 - 214
  • [38] Potent single agent activity and tumor selectivity of bortezomib in mantle cell lymphoma: First impressions from a randomized phase II study of EPOCH-rituximab-bortezomib in untreated mantle cell lymphoma.
    Wiestner, A
    Dunleavy, K
    Rizzatti, EG
    Liu, H
    Marti, GE
    White, T
    Wilson, W
    BLOOD, 2005, 106 (11) : 266B - 266B
  • [39] Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma
    Romaguera, Jorge
    Fayad, Luis
    McLaughlin, Peter
    Pro, Barbara
    Rodriguez, Maria Alma
    Wang, Michael
    Weaver, Pamela
    Hartig, Kimberly
    Kwak, Larry
    Feldman, Tatyana
    Smith, Judy
    Ford, Peggy
    Goldberg, Stuart
    Pecora, Andrew
    Goy, Andre
    BLOOD, 2008, 112 (11) : 1049 - 1049
  • [40] Cladribine (2-CDA) and rituximab combination treatment for patients with Waldenstrom's macroglobulinemia (WM) or small lymphocytic lymphoma (SLL): Clinical preliminary reports of a multicenter study
    Laszlo, D.
    Andreola, G.
    Rabascio, C.
    Mancuso, P.
    Calabrese, L.
    Pinto, A.
    Fabbri, A.
    Rigacci, L.
    Manz, C.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 226 - 227
12345